Abstract

DRUGS USED IN THE TREATMENT OF COVID-19

M. Sivagamy*, R. Nirmala, B. Prathap, R. Ajay, S. Gokul, S. Iyswarya, N.V. Suriya

.

Abstract

The global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute. (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in Wuhan, China, in December2019, and has since spread worldwide. As of April 5, 2020, there have been more than 1.2 million reported cases and 69000 deaths in more than 200 countries. This novel Betacoronavirus is similar to severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus(MERS-CoV); based on its genetic proximity, it likely originated from bat-derived coronaviruses with spread via an unknown intermediate mammal host to humans. The viral genome of SARSCoV- 2 was rapidly sequenced to enable diagnostic testing, epidemiologic tracking, and development of preventive and therapeutic strategies. Currently, there is no evidence from randomized clinical trials (RCTs) that any potential therapy improves outcomes in patients with either suspected or confirmed COVID-19. There are no clinical trial data supporting any prophylactic therapy. More than 300 active clinical treatment trials are underway. This narrative review summarizes current evidence regarding major proposed treatments, repurposed or experimental, for COVID-19 and provides a summary of current clinical experience and treatment guidance for this novel epidemic coronavirus.

Keywords: COVID-19, Vaccines, Remdesivir, Chloroquine/Hydroxychloroquine, Ivermectin, Lopinavir, Ritonavir, Precaution, Treatment.